penile%20cancer
PENILE CANCER

Penile cancer is a rare type of malignant growth that occurs on the skin or tissues of the penis.

It often presents as a palpable visible penile lesion w/ signs that may include pain, bleeding, discharge or a foul odor.

The lesion may be fungating, nodular or ulcerative and may be concealed by phimosis.


Penile%20cancer Management

Monitoring

  • Goal is to detect early recurrence as majority of recurrences occur within the first 2-5 years of primary treatment
    • Local recurrence rate is higher in the first 2 years of follow-up after penile-preserving surgery than with penectomy
    • Regional recurrences happen within 2 years after dynamic sentinel node biopsy (DSNB) or inguinal lymph node dissection (ILND)
    • As life-threatening metastases are rare after 5 years, follow-up can be stopped after 5 years provided patient can reliably regularly perform self-examination & immediately report any changes
  • Follow-up is also significant in the detection & management of complications arising from treatment
  • Clinical evaluation includes examination of the penis & inguinal region
    • If clinical evaluation has abnormal results or patient is obese or had a prior inguinal surgery, consider imaging with an ultrasound, computed tomography (CT) or magnetic resonance imaging (MRI) scans
  • Additional imaging with a chest x-ray or CT or an abdominopelvic CT or MRI scan may be requested for surveillance in N2 or N3 lymph nodes
  • Follow-up schedule for the primary tumor includes the following:
    • Clinical evaluation every 3 months in the first 2 years & every 6 months in the subsequent 3 years after penile-preserving treatment
    • Clinical evaluation every 6 months in the first 2 years & annually in the subsequent 3 years after penectomy
  • Follow-up schedule for lymph node involvement includes a clinical evaluation every 3-6 months in the first 2 years & every 6-12 months in the subsequent 3 years

Prevention

 Recurrent Disease

  • Up to 30% of all patients with penile cancer will later recur
    • A higher risk of recurrence can be seen in T2 to T4 tumors or grade 3 tumors of any T stage
  • Local recurrent disease can be managed depending on the type of recurrence, ie penile or inguinal
    • Salvage penectomy (eg partial or total) is performed in most cases & may also be done if initial radiation therapy failed or if invasion of corpora cavernosa is present
    • Consider salvage penile-sparing options if without invasion of the corpora cavernosa
    • For a localized inguinal recurrence, multimodality treatment may be given using systemic chemotherapy, radiation therapy, &/or surgical resection
      • Phase I & II clinical trials using new chemotherapeutic drugs or biologicals may be offered to patients with nodal recurrence uncontrolled by above local treatment measures
  • A nodal re-evaluation should be performed in patients undergoing recurrent penile tumor resection as a prophylactic inguinal staging procedure (ie DSNB or ILND) can be a treatment option if a prior node dissection has not been performed
  • For patients with fixed inguinal nodes or high tumor burden not amenable to resection, radiation therapy to relieve pressure from tumor compression or further treatment with palliative chemotherapy may be advised
Editor's Recommendations
Most Read Articles
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
Tristan Manalac, Yesterday
While antibody titres against SARS-CoV-2 wane with time, the immune system is capable of producing memory B-cells that can last for at least 6 months after infection, suggesting that the body will be able to protect itself in the case of re-exposure, according to a new study.
Jairia Dela Cruz, 5 days ago
Spending too much time sitting cannot be good for the body, and rising to one's feet breaks up such a behaviour and yields small, but meaningful, reductions in certain cardiovascular disease (CVD) risk factors, according to the results of a meta-analysis.